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Summary
Background WHO’s Third Global Patient Safety Challenge, Medication Without Harm, focused on reducing the 
substantial burden of iatrogenic harm associated with medications by 50% in the next 5 years. We aimed to assess 
whether the number and type of medication errors changed as an electronic prescribing system was optimised over 
time in a UK hospital.
Methods We did a prospective observational study at a tertiary-care teaching hospital. Eight senior clinical pharmacists 
reviewed patients’ records and collected data across four adult wards (renal, cardiology, general medical, and 
orthopaedic surgical) over a 2-year period (from Sept 29, 2014, to June 9, 2016). All medication errors and potential and 
actual adverse drug events were documented and the number of medication errors measured over the course of four 
time periods 7–10 weeks long. Pharmacists also recorded instances where the electronic prescribing system contributed 
to an error (system-related errors). A negative-binomial model and a Poisson model were used to identify factors 
related to medication error rates.
Findings 5796 primary errors were recorded over the four time periods (period 1, 47 days [Sep 29–Dec 2, 2014]; period 2, 
38 days [April 20–June 12, 2015, for the renal, medical, and surgical wards and April 20–June 15, 2015, for the cardiology 
ward]; period 3, 35 days [Sep 28–Nov 27, 2015] for the renal ward, 37 days [Sep 28–Nov 23, 2015] for the medical ward, 
and 40 days [Sep 28–Nov 20, 2015] for the cardiology and surgical wards; and period 4, 37 days [Feb 22–April 15, 2015] 
for the renal and medical wards and 39 days for the cardiology [April 13–June 7, 2015] and surgery [April 18–June 9, 2015] 
wards; unanticipated organisational factors prevented data collection on some days during each time period). There 
was no change in the rate of primary medication errors per admission over the observation periods: 1·53 medication 
errors in period 1, 1·44 medication errors in period 2, 1·70 medication errors in period 3, and 1·43 medication errors 
in period 4, per admission. By contrast, the overall rate of different types of medication errors decreased over the four 
periods. The most common types of error were medicine-reconciliation, dose, and avoidable delay-of-treatment 
errors. Some types of errors appeared to reduce over time (eg, dose errors [ from 52 errors in period 1 to 19 errors in 
period 4, per 100 admissions]), whereas others increased (eg, inadequate follow-up of therapy [ from 12 errors in 
period 1 to 24 errors in period 4, per 100 admissions]). We also found a reduction in the rates of potential adverse drug 
events between the first three periods and period 4. 436 system-related errors were recorded over the study period.
Interpretation Although the overall rates of primary medication errors per admission did not change, we found a 
reduction in some error types and a significant decrease in the rates of potential adverse drug events over a 2-year 
period, during which system optimisation occurred. Targeting some error types could have the added benefit 
of reducing others, which suggests that system optimisation could ultimately help improve patient safety and 
outcomes.
Funding No funding.
Copyright © 2019 The Author(s). Published by Elsevier Ltd. This is an Open Access article under the CC BY-NC-ND 4.0 
license.
Introduction
The UK National Health Service (NHS) aims to become 
one of the safest health-care systems in the world.1,2 
Globally, the cost associated with medication errors has 
been estimated to be US$42 billion per year.3 In 2017, 
WHO announced its Third Global Patient Safety 
Challenge, Medication Without Harm, which was aimed 
at reducing the substantial burden of iatrogenic harm 
associated with medications by 50% in the following 
5 years.3
The previous UK Secretary of State for Health and Social 
Care, Jeremy Hunt, announced how a new government 
initiative to reduce medication and prescribing errors 
in England would concentrate on the use of electronic 
prescribing systems in hospitals.4 However, imple men-
tation of electronic prescribing has been slow and, indeed, 
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further funding has been allocated to speed up imple-
mentation of these systems in 13 English hospital trusts 
by 2021.
Electronic prescribing, which usually refers to the 
ordering or prescribing of medication electronically, has 
been shown to reduce the risk of medication errors and 
adverse drug events.5 A systematic review and meta-
analysis reported a 50% reduction in preventable adverse 
drug events with the implementation of electronic 
prescribing systems in the hospital setting.6 However, 
most of the studies included in the systematic reviews5,6 
were done in the USA using extensively customised 
electronic prescribing systems. One UK study, done 
more than 10 years ago on a general surgery ward, 
suggested that a closed-loop system including electronic 
prescribing, automated dispensing, barcode patient 
identification, and electronic medication-admin istration 
records could stop two prescribing errors per 100 pre-
scriptions written.7 However, electronic pre scribing 
systems are likely to have changed quite substantially 
over the past 10 years, with more robust clinical decision 
support.8 Furthermore, studies9–11 have also shown how 
these systems can con tribute to new types of errors, 
specifically those associated with use of the system 
(eg, drop-down menu selection errors). Up-to-date 
evidence from the UK about the incidence and types of 
errors occurring in hospitals is needed to guide the 
decisions of policy makers and managers.
We did the largest UK study to date to examine whether 
the rate of medication error per admission and types of 
errors changed as changes were made to an electronic 
prescribing system over time. We also explored whether 
some types of medication errors tended to occur together 
(or clustered) because this could help identify how to 
target error prevention strategies to reduce multiple error 
types and assessed the incidence and preventability of 
actual or potential adverse drug events. Finally, we also 
assessed whether the system functionality or design of the 
electronic prescribing system could have contributed to 
the errors, which we described as system-related errors.
Methods
Study design and participants
This was a prospective observational study done at 
a tertiary-care teaching hospital with approximately 
1800 beds, belonging to one of the largest NHS trusts in 
the UK. The study was done across a range of clinical 
settings including renal, cardiology, general medical, 
and orthopaedic surgical services, with approximately 
20–30 beds per each of the four adult wards. All newly 
admitted patients to the study wards were included. Data 
were collected by clinical pharmacists at four separate time 
periods which were 7–10 weeks long, in line with a previous 
study.12 A decision was made to avoid data collection during 
the month of August to limit bias from errors made by 
newly qualified prescribers during the junior-doctor 
handover period. Eight senior clinical pharmacists who 
were employed as permanent members of the hospital 
pharmacy team collected 3864 h of data in total.
The hospital trust originally implemented a commercial 
elec tronic prescribing system in adult inpatient wards 
between Oct 6, 2008, and March 25, 2011. Approximately 
5720 medication orders were written daily across the trust; 
this included 70–180 orders daily on each of our four study 
wards. Chemotherapy orders were entered into a separate 
electronic prescribing system and patient-controlled 
Research in context
Evidence before this study
In 2014, Nuckols and colleagues did a systematic review and 
meta-analysis to assess the effectiveness of Computerized 
Provider Order Entry (CPOE) at reducing preventable adverse 
drug events in hospital-related settings and examine the 
reasons for heterogeneous effects on medication errors. 
They identified studies using MEDLINE, Cochrane Library, 
Econlit, web-based databases, and bibliographies of previous 
systematic reviews. Implementing CPOE was associated with 
a greater than 50% decline in preventable adverse drug events, 
although the included studies used weak designs and were 
mostly done in the USA using extensively customised electronic 
prescribing systems. We further searched Ovid MEDLINE for 
articles published from Jan 1, 2014, to July 10, 2019, using 
search terms relating to medical order entry systems or 
electronic prescribing, or decision-support systems, clinical and 
medication errors, and hospitals . Specifically, we used the 
medical subject headings “Medical Order Entry Systems/ OR 
Electronic Prescribing/, OR Decision Support Systems, Clinical
AND Medication Errors/ AND Hospitals/”. Our review revealed 
only a few additional studies that focused on specific clinical 
areas such as intensive care units or discharge prescriptions.
Added value of this study
This is the largest UK study to examine whether the overall rate 
of medication errors per admission and the types of errors 
changed over time during the optimisation of an electronic 
prescribing system. We found no significant change in the rates 
over time; however, the rate of some types of errors (eg, dose) 
decreased across the study period, whereas the rate of other 
errors (eg, inadequate follow-up of therapy) increased over 
time. Our study revealed how some error types, such as dose 
and medicine-reconciliation errors, were more likely to occur 
together.
Implications of all the available evidence
To reduce the substantial burden of iatrogenic harm associated 
with medications and maximise the effect of future clinical 
decision support systems on reducing errors in the hospital 
setting, electronic prescribing systems will need to monitor for 
those types of error that are likely to occur together.
Correspondence to: 
Dr Sarah P Slight, School of 
Pharmacy, Newcastle University, 
Newcastle upon Tyne NE1 4LP, UK 
sarah.slight@newcastle.ac.uk
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analgesia and epidurals, intravenous fluids, and high-
frequency eye medication were ordered on paper charts. 
Pharmacists were able to clinically screen and validate 
medication orders elec tronically and nurses documented 
administrations in the system.
Ethics approval was obtained from the Health Research 
Authority National Research Ethics Service Committee 
North East-Sunderland 14/NE/0072 (IRAS project 
ID 141106) and Trust R&D Permission (project 6785). 
The Health Research Agency—Confidentiality Advisory 
Group confirmed that informed consent from patients 
was not necessary for this study.
Procedures
Serial changes were made to the system over the four data 
collection periods. During period 1, the system consisted 
of the most basic features with little clinical decision 
support. Orders were typically selected from a locally 
configured medications catalogue with structured order 
sentences via a drop-down menu, which included the 
medication name and a range of routes, doses, and 
frequencies (eg, omeprazole 20 mg orally once per day). 
Drug allergy checks were active and prescribers and 
pharmacists were notified about a small number of drug–
drug interactions and drug laboratory checks using a pop-
up alert after these orders had been made. Order sets (a 
group of clinically related orders grouped together for 
prescriber convenience and efficiency) were also used. 
Immediately before period 1, pharmacy staff were granted 
access to the NHS Summary Care Record (an electronic 
record of important patient information, created from 
general-practice medical records in England). This access 
was extended to medical staff in acute settings in the fol-
lowing months. In period 2 dosage alerts for certain 
medications were introduced and pharmacy staff were 
informed when a range of high-risk medications were 
prescribed (eg, anti convulsants and clozapine). In period 3, 
a new version of the electronic prescribing system was 
installed, which resulted in changes to the visual display 
and users being provided with a link to access the patient’s 
previous electronic outpatient letters and details of their 
clinic appoint ments. Furthermore, from this point, 
prescribers were able to prescribe insulin on the electronic 
prescribing system, which offered options for the user to 
prescribe short-acting, intermediate-acting, or long-acting 
insulin. In period 4, a number of high-risk drug–drug 
interaction alerts were introduced to prescribers and 
pharmacists. Order sets for omeprazole infusions and 
peritoneal dialysis were also used. In addition, email 
notifications were sent to a named clinician if certain 
medications were ordered (eg, an email was sent to a 
designated clinician if a novel oral anticoagulant was 
initiated for a patient admitted to care in the ward for older 
patients). Further detail about changes that were made to 
the system over time are outlined in the appendix (pp 1, 2).
All patients admitted to one of the four study wards 
during the data collection periods were reviewed daily by 
a pharmacist to reveal any medication-related problems. 
Each ward was assigned a specific clinical pharmacist 
to collect data during the study period. Each day, the 
pharmacist would meet any new patients and do an 
advanced medication review, assessing each patient’s 
in-patient electronic and paper drug chart(s) alongside 
any blood test results, observations, and medical notes.13 
Pharmacists considered the patient’s usual medication-
taking behaviour. However, any drug-related problems 
associated with medication adherence or administration 
while at home were addressed but not included in this 
study as a medication error. Pharmacists would also 
perform a daily review of each inpatient’s electronic and 
paper drug chart(s) to identify new orders and any 
unresolved errors. The potential consequences of errors 
were assessed using the pharmacist’s clinical knowledge 
and judgement about the patient at the time the drug was 
prescribed. Furthermore, a more detailed investigation 
of the patient’s medical notes was done if the reviewer 
identified an adverse drug event (eg, major bleeding, 
new confusion, nausea, constipation, cardiac arrest, or 
changes to blood test results). This detailed investigation 
involved reviewing the patient’s full medical notes, 
including their electronic medication chart and any 
blood results taken, and making an assessment about 
whether the drug error could have possibly caused the 
adverse outcomes identified. All medication errors and 
actual and potential adverse drug events were docu-
mented on a data collection form. Incidents were 
excluded if a patient injury was not clearly drug related.
All incidents were evaluated as to whether they 
represented medication errors as per the definitions in a 
Harvard University study (Cambridge, MA, USA).12
Medication errors were classified by type using a 
modified classification structure (appendix pp 3–5). 
Medi cine-reconciliation error was added to capture 
errors that occurred at the medicine-reconciliation stage. 
Pharmacists could select one primary error type and 
multiple secondary error types for one medication order 
(figure 1). Error options were dose error (eg, inappropriate 
dose), route error (eg, route not specified or inappropriate 
route), frequency error (eg, frequency omitted), strength 
error (eg, strength inappropriate), formulation error (eg, 
formulation omitted), administration error, substitution 
(eg, wrong drug given), unnecessary drug, inappropriate 
drug, generic-name or brand-name error, known allergy to 
drug, duplication, drug–drug interaction, contra indication, 
inadequate follow-up of therapy, avoidable delay of 
treatment, premedication not ordered, preparation error, 
medicine-reconciliation error, course length or duration, 
policy not followed, monitoring not requested, monitoring 
requested but not done, monitoring results not available, 
monitoring results available but not acted upon and other. 
Different types of errors could occur at different stages 
of the medication use process (medicine-reconciliation, 
prescribing, verification or dispensing, administration, 
and monitoring stage; figure 1). Primary errors were 
See Online for appendix
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defined as the main error that occurred with a specific 
order and secondary errors were errors related to that. 
For example, the pharmacist would select medicine-
reconciliation error as the primary error if a medication 
was prescribed incorrectly on admission. They could also 
select dose error as a secondary error if the error was 
related to the dose. Regular meetings were held between 
the study team and senior clinical pharmacists to ensure 
consistency in error classification. Pharmacists were also 
asked to record if the electronic prescribing system could 
have contributed to the occurrence of the medication error 
in this UK study (which could have occurred, for example, 
if the wrong drug was selected from a drop-down menu 
list as it was located next to a similarly named drug). 
Pharmacists could select one or more options from a set of 
predetermined system-related errors (appendix p 6).
Incidents suspected of being actual or potential adverse 
drug events were evaluated by the data-collection ward 
pharmacist reviewer and classified into one of four 
categories as adverse drug event, potential adverse drug 
event, medication error with little potential for harm, or no 
error or adverse drug event. Potential adverse drug events 
were categorised as intercepted or not intercepted. All 
adverse drug events and potential adverse drug events 
were classified according to severity: fatal, life-threatening, 
serious (eg, decrease in blood pressure), or significant 
(eg, nausea), similar to a previous study.12 Preventability 
was classified as definitely preventable, probably pre-
ventable, probably not preventable, and definitely not 
preventable. A non-preventable adverse drug event was 
defined as “an injury due to a medication where there is no 
error in the medication process”14 (eg, an allergic reaction 
in a patient not known to be allergic to a medication). This 
four-point scale was collapsed into preventable and not 
preventable during the analysis stage. All classifications 
were double-checked by a second reviewer (CLT), who 
was not masked, and any discrepancies or queries were 
discussed with reclassification of the adverse drug event, if 
necessary. Reviewers considered an adverse drug event 
preventable if it was due to an error or was preventable by 
any means currently available. The pharmacist who did 
the chart review also recorded the evidence that supported 
their decision to classify the error. They could select that 
there was little or no evidence, slight to modest evidence, 
moderate evidence, strong evidence, or virtually certain 
evidence. A working copy of medication error scenarios 
and the appropriate classification was maintained by the 
pharmacist reviewers during meetings and referred to 
periodically to aid classification.
Outcomes
The main outcomes of the study were the rate of medi-
cation error per admission and the type of medication 
errors selected by the data collection pharmacist. We 
defined medication errors as “errors in the process of 
ordering, dispensing, or administering a medication, 
regardless of whether an injury occurred or whether the 
potential for injury was present”.12 As secondary outcomes, 
we also collected data on adverse drug events (both 
preventable and non-preventable), and potential adverse 
drug events defined as “errors with the potential for harm 
that did not result in an injury”.12 Potential adverse drug 
events included both errors that were intercepted before 
the medication reached the patient and non-intercepted 
errors that did reach the patient but did not cause injury. 
This study captured all medication errors that occurred at 
specified time periods, which might or might not have 
resulted in patient harm. We also assessed the co-
occurrence (clustering) of error types and factors related 
to medication error rates, including age, number of 
medications, sex, ward, and period.
Statistical analysis
Medication error rates were calculated as the number of 
primary medication errors per admission or per collec-
tion day in each of the study periods. Patients could have 
Figure 1: Flow chart showing medication error types according to stage in the medication use process
Medicine-reconciliation
stage
Prescribing stage Verification or dispensing
stage
Administration stage Monitoring stage
• Dose error
• Route error
• Frequency error
• Strength error
• Formulation error
• Substitution error
• Premedication not ordered
• Course length or duration
• Policy not followed
• Failure to recognise 
drug–drug interaction
• Substitution error
• Avoidable delay of 
treatment
• Preparation error
• Administration error
• Avoidable delay of 
treatment
• Monitoring error
• Inadequate follow-up
of therapy
Inappropriate drug 
Generic-name or 
brand-name error 
Medication prescribed; 
patient had a documented 
allergy 
Medication prescribed; 
patient on duplicate medicine 
Unnecessary drug 
Avoidable delay of
treatment 
Failure to recognise
contraindication 
Medicine-reconciliation error 
on admission or discharge
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had more than one error recorded per day over their 
admission; these errors were summed over their stay and 
recorded as one entry per patient. Each error recorded on 
a given day was counted again on the following days if it 
was not resolved, with the expectation that pharmacists 
would take steps to resolve all errors on the same day 
they were identified, such that each error would only be 
counted once. Models for count data (ie, the negative-
binomial and Poisson models) were used to identify 
factors related to medication error rates in the four wards 
during the study periods. The total number of days each 
patient stayed in the hospital was used as an offset in 
these models. The number of medication error types was 
calculated from the incidence of primary and secondary 
errors. The study periods were considered as categorical 
variables in the models to test whether the incidence rate 
ratio (IRR) of medication errors differed between the 
study periods and wards.15
The Poisson and negative-binomial models were also 
used to test for equality of error-type rates per admission 
during the study periods. p values were obtained from a 
likelihood ratio χ² test by comparing an empty model 
with a model comprising of only a categorical period 
variable. The patients admitted to all study wards in each 
period were used as an offset in the model.
Further analysis of cases in which medicine-reconcili-
ation errors were selected as the primary error type was 
also done with an agglomerative hierarchical clustering 
approach to identify groups of medication error types 
exhibiting both intracluster similarity and intercluster 
dissimilarity, according to whether a particular medica-
tion error type occurred or not. The co-occurrence of an 
error type (ie, similarity) was based upon the Tanimoto 
coefficient, which is an appropriate distance measure for 
binary data.16 Frequencies were used to summarise the 
frequencies of system-related errors for each study period. 
The significance threshold was set at p=0·05. We focused 
on medicine-reconciliation errors as they were the most 
commonly occurring error type for this exploratory 
analysis.
Role of the funding source
There was no specific funding for this study. The staff 
who contributed their time to data collection, analysis, 
and interpretation were employed by Newcastle 
University and Newcastle Upon Tyne Hospitals NHS 
Foundation Trust. No funding has been received to write 
this Article from a pharmaceutical company or other 
agency. The corresponding author had full access to all 
the data in the study and had final responsibility for the 
decision to submit for publication.
Results
Study periods varied in duration between study wards, 
mainly because of unanticipated organisational factors 
that prevented data collection on a few days during each 
period. Period 1 lasted 47 days (Sep 29–Dec 2, 2014); 
period 2 lasted 38 days (April 20–June 12, 2015, for 
the renal, medical, and surgical wards and 
April 20–June 15, 2015, for the cardiology ward); period 3 
lasted 35 days (Sep 28–Nov 27, 2015) for the renal ward, 
37 days (Sep 28–Nov 23, 2015) for the medical ward, 
and 40 days (Sep 28–Nov 20, 2015) for the cardiology 
and surgical wards; and period 4 lasted 37 days 
(Feb 22–April 15, 2015) for the renal and medical wards 
and 39 days for the cardiology (April 13–June 7, 2015) and 
surgery (April 18–June 9, 2015) wards. There were 
1150 patients admitted to study wards in period 1, 930 in 
period 2, 824 in period 3, and 920 in period 4. There were 
15·8 medications ordered per admission in period 1, 
13·7 in period 2, 15·9 in period 3, and 13·1 in period 4. 
There were about nine to 11 regular medications ordered 
per patient admission and less than one medication 
ordered but held or suspended (usually for a clinical 
reason) per admission across the four study periods 
(table 1). A trend test for medication error rates per 
admission showed no significant results (p=0·88). There 
were significant diff erences between error rates per 
admission during the four periods (likelihood ratio χ² test 
p<0·0001). Further analyses showed that there 
were significant differences between periods 2 and 3 
(p=0·0005, adjusted for multiple tests) and between 
periods 3 and 4 (p=0·0004, adjusted for multiple tests).
The rate of primary medication errors per admission 
did not change significantly during the four periods 
(1·53 medication errors in period 1, 1·44 medication 
Period 1 Period 2 Period 3 Period 4
Duration, days 47 38 38 38
Patients admitted to 
all study wards
1150 930 824 920
Patient-days 5023 4129 3780 3682
Medications ordered 18 170 12 742 13 100 12 023
Medications ordered 
per patient-day
3·62 3·09 3·47 3·27
Medications ordered 
per admission
15·80 13·70 15·90 13·07
Regular medications 12 318 8465 8925 8488
Suspended 
medications
705 534 525 535
Regular medications 
ordered per admission
10·71 9·10 10·83 9·23
Suspended 
medications per 
admission
0·61 0·57 0·64 0·58
Total number of 
primary medication 
errors
1762 1337 1377 1320
Primary medication 
errors per admission*
1·53 1·44 1·70 1·43
*We used the likelihood ratio χ² test to compare the equality of the medication 
error rates across the four study periods and obtained p<0·0001 (χ²=20·76; 
3 degrees of freedom).
Table 1: Overview of medications ordered across each of the study periods
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errors in period 2, 1·70 medication errors in period 3, 
and 1·43 medication errors in period 4; table 1). By 
contrast, the overall rate of different types of medication 
errors decreased over the four periods (table 2). The 
most common error type (calculated from the total of 
primary and second ary errors) was the medicine-
reconciliation error, with 85 errors in period 1, 84 errors 
in period 2, 85 errors in period 3, and 72 errors in 
period 4 per 100 admissions (table 2). When the 
medicine-reconciliation error was selected as the 
primary error, 351 (47%) of 753 patients in period 1, 
215 (33%) of 654 patients in period 2, 121 (24%) of 
514 patients in period 3, and 115 (39%) of 293 patients in 
period 4 also had a secondary dose error recorded 
(appendix p 7). The next most common error types (both 
primary and secondary errors) were dose error (with 
52 errors in period 1, 41 errors in period 2, 27 errors in 
period 3, and 19 errors in period 4 per 100 patient 
admissions) and avoidable delay-of-treatment error (with 
30 errors in period 1, 25 errors in period 2, 24 errors in 
period 3, and two errors in period 4 per 100 admissions). 
Although the rate of dose errors (52 errors in period 1 vs 
19 errors in period 4 per 100 admissions), course-length 
or course-duration errors (seven errors vs three errors 
per 100 admissions), and inappropriate-drug errors 
(13 errors vs five errors per 100 admissions) decreased, 
the rate of the error classified as inadequate follow-up of 
therapy (12 errors vs 24 errors per 100 admissions) 
increased over time (table 2). Except for when medicine-
reconciliation error was the primary error, we did not 
distinguish between primary and secondary errors in 
our analyses.
The rates of actual adverse drug events decreased from 
period 1 to period 3; however, the rate went up again in 
period 4. There was a significant decrease in potential 
adverse drug events across the four study periods from 
ten per 100 admissions, in period 1, to six per 100 admis -
sions, in period 4 (p=0·0376; table 3).
436 system-related errors were recorded over the four 
study periods. Of these errors, 81 (19%) were inflexi bility 
errors (37 recorded in period 1, 20 in period 2, 21 in 
period 3, and three in period 4), which included 
inflexibility in order screens (eg, when attempting to 
modify a medication order), and 286 (66%) were system-
related errors classified as other (ie, not selection, 
placement, hazardous, keypad, or inflexibility errors; 
70 in period 1, 68 in period 2, 69 in period 3, and 79 in 
period 4; table 4). The least common system-related error 
was placement error (eg, listing penicillamine in the 
middle of various penicillin products, resulting in 
wrong drug selection) with none recorded in periods 1, 3, 
and 4, but with three errors (rate <1 per 100 admissions) 
recorded in period 2. There was no significant change in 
the reporting of system-related errors over the study 
periods (p=0·42).
The clustering of medication error types for period 1, 
when medicine reconciliation was considered as the 
primary error, shows how dose, avoidable delay-of-treat-
ment, and frequency errors were likely to occur together 
(figure 2). These three error types also tended to occur 
Period 1, n=1150 Period 2, n=930 Period 3, n=824 Period 4, n=920 p value
Number 
of errors
Error rate 
per 100 
admissions
Number 
of errors
Error rate 
per 100 
admissions
Number 
of errors
Error rate 
per 100 
admissions
Number 
of errors
Error rate 
per 100 
admissions
Dose 598 52 379 41 224 27 172 19 <0·0001
Frequency 134 12 121 13 150 18 114 12 0·0010
Formulation 83 7 48 5 64 8 44 5 0·21
Unnecessary drug 154 13 93 10 94 11 92 10 0·069
Inappropriate drug 144 13 136 15 106 13 47 5 <0·0001
Medication prescribed; patient on 
duplicate medicine
119 10 60 6 74 9 57 6 0·0017
Inadequate follow-up of therapy 141 12 166 18 164 20 225 24 <0·0001
Avoidable delay of treatment 341 30 228 25 194 24 19 2 <0·0001
Medicine reconciliation 975 85 781 84 697 85 662 72 0·0031
Course length or course duration 78 7 68 7 72 9 28 3 <0·0001
Policy not followed 190 17 167 18 187 23 162 18 0·016
Other* 80 7 321 35 171 21 130 14 <0·0001
Total 3037 264 2568 276 2197 267 1752 190 <0·0001
In all tests, the Poisson model performed better than the negative binomial model. p values compare the equality of rates in the four study periods. Error types with a rate of 
fewer than five errors per 100 admissions have been removed (these included route error, strength error, administration error, substitution error, generic-name or brand-name 
error, medication prescribed that patient had a documented allergy to, failure to recognise drug–drug interaction, failure to recognise contraindication, monitoring not 
requested, monitoring results available but not acted upon). *Included error types (such as spelling errors and allergy status not documented) that were not included in the 
data collection form but were recorded as part of the study.
Table 2: The rates of different types of medication errors per 100 admissions across four study periods (calculated from the total number of primary and 
secondary medication errors)
Articles
www.thelancet.com/digital-health   Published online October 31, 2019    https://doi.org/10.1016/S2589-7500(19)30158-X 7
together in periods 2 and 3 (appendix pp 8–11). Strength 
and generic-name or brand-name errors were more likely 
to occur together in periods 1 and 2, as were errors 
classified as inadequate follow-up of therapy, and policy-
not-followed errors in periods 2 and 4 (appendix pp 8–11).
We found that the negative-binomial model fitted our 
data better than the Poisson model (the Akaike infor-
mation criteria was 12489·15 for the negative-binomial 
model and 15506·82 for the Poisson) and hence present 
the results that we obtained from this model here. Older 
patients were found to be more at risk of medication 
errors than younger patients, with an IRR of medication 
error of 1·004 (95% CI 1·001–1·007) per year of increase 
in age (p=0·0230; table 5). Total number of medications 
was also an important risk factor for medication error, 
with an IRR of medication error of 1·022 (1·017–1·026; 
p<0·0001) per medication added. The error rate for 
female patients was 1·2 times higher than for male 
patients (with an average of 0·31 errors per day [95% CI 
0·29–0·34] for female patients and 0·27 errors per day 
[0·25–0·29] for male patients; data not shown). The 
estimated IRRs were dependent on the ward and the 
period in which patients were reviewed.
Discussion
We recorded more than 5000 primary errors in this study, 
the most common types being medicine-reconciliation, 
dose, and avoidable delay-of-treatment errors. Although 
we found no significant change in the overall rate of 
medication errors per admission, the rates of dose and 
inappropriate-drug errors were found to have reduced 
over time. There was also a significant decrease in 
potential adverse drug events across the four study 
periods. It is possible that the cumulative effect of system 
Period 1, n=1150 Period 2, n=930 Period 3, n=824 Period 4, n=920 p value
Number 
of errors
Error rate 
per 100 
admissions
Number 
of errors
Error rate 
per 100 
admissions
Number 
of errors
Error rate 
per 100 
admissions
Number 
of errors
Error rate 
per 100 
admissions
ADE
ADE 34 3 20 2 15 2 29 3 ··
Potential ADE 113 10 110 12 90 11 59 6 ··
Total actual and potential ADEs 147 13 130 14 105 13 88 10 0·0376
Severity of ADEs
Fatal 0 0 0 0 0 0 0 0 ··
Life-threatening 1 <1 0 0 0 0 3 10 ··
Serious 7 1 3 0 4 0 6 1 ··
Significant 26 2 17 2 11 1 20 2 ··
Total severity of ADEs 34 3 20 2 15 2 29 3 0·22
Severity of potential ADEs
Life-threatening ADE 12 1 11 1 8 1 4 <1 ··
Potential for serious 87 8 58 6 73 9 28 3 ··
Potential for significant 14 1 41 4 9 1 27 3 ··
Total severity of potential ADEs 113 10 110 12 90 11 59 6 0·0007
p values compare the equality of rates in the four study periods. ADE=adverse drug events.
Table 3: Incidence and preventability of ADEs and potential ADEs
Period 1, n=1150 Period 2, n=930 Period 3, n=824 Period 4, n=920
Number of 
system-related 
errors
Rate per 
100 admissions
Number of 
system-related 
errors
Rate per 
100 admissions
Number of 
system-related 
errors
Rate per 
100 admissions
Number of 
system-related 
errors
Rate per 
100 admissions
Selection error 9 (7%) 1 5 (5%) 1 8 (7%) 1 16 (16%) 2
Placement error 0 0 3 (3%) <1 0 0 0 0
Hazardous error 7 (6%) 1 5 (5%) 1 1 (1%) <1 0 0
Keypad error 0 0 5 (5%) 1 9 (8%) 1 1 (1%) <1
Inflexibility error 37 (30%) 3 20 (19%) 2 21 (19%) 3 3 (3%) <1
Other 70 (57%) 6 68 (64%) 7 69 (64%) 8 79 (80%) 9
Total 123 11 106 11 108 13 99 11
Data are n (%) or rates per 100 admissions. The p value testing global trend across the four study periods was 0·42.
Table 4: System-related errors and event rate by period
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optimisation, including clinical decision support and 
system design changes, contributed to this finding, 
although further research is needed to confirm this. 
The clustering of different types of errors appeared to 
change across the four time periods. This finding is 
important because future clinical decision support sys-
tems will need to monitor and prevent specific types of 
error that are more likely to occur together.
The medication error rates are similar to those reported 
by Westbrook and colleagues at two Australian hospi-
tals using commercial electronic prescribing systems.17 
Shulman and colleagues noted a significant reduction in 
medication errors made after the implementation of an 
electronic prescribing system in the University College 
London Inten sive Care Unit (London, UK) in 2002, which 
the authors suggested could have been due to improve-
ments made to the system in light of experience.18 Similar 
to our study, Van Doormaal and colleagues also observed 
a reduction in dosing errors across four wards in 
two hospitals in the Netherlands more than 10 years ago, 
but they did not detect a significant change in therapeutic 
errors (eg, drug interactions, contra indications, and 
duplicate therapy) or in preventable adverse drug events, 
possibly because of the insufficiently advanced clinical 
decision support used.19 We also found that the incidence 
of some error types, such as errors due to inadequate 
follow-up of therapy, increased over time and plan to 
explore whether advanced clinical decision support could 
reduce this increase by, for example, using targeted 
reminders for clinicians. We found that the rate of 
some types of medication error (eg, dose, strength, and 
inappropriate-drug errors) declined over time. A few 
checks were intro duced into the system that could have 
contributed to this reduced rate, including dosing alerts 
and order sets (which presents prescribers with a list of 
medications and approved doses for a specific condition, 
such as a peritoneal dialysis order set). Further controlled 
studies would be helpful in determining the effect and 
any unintended consequences (such as alert fatigue) of 
spe cific forms of clinical decision support and system 
design changes.
Our clustering analysis revealed how some secondary 
errors (eg, dose error, avoidable delay-of-treatment, and 
frequency errors) were more likely to occur together. This 
clustering is possibly due to the locally configured order 
sentences—ie, as each medication name was linked to a 
route, dose, and frequency, selection of the wrong dose 
would also be linked to an incorrect frequency.
Similarly, these results also showed that errors due to 
policy not followed and inadequate follow-up of therapy 
were more likely to occur together, which suggests how 
further improvements could be made to the electronic 
system to both improve adherence and patient follow-up. 
Little has been published about how errors are clustered, 
Figure 2: Clustering of medication error types for period 1, when medicine reconciliation was considered as 
the primary error
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Incidence rate ratio 
(95% CI)
p value
Model intercept 0·166 (0·120–0·228) <0·0001
Age, per 1-year increase 1·004 (1·001–1·007) 0·0230
Total medication, per added 
medication
1·022 (1·017–1·026) <0·0001
Sex* 1·172 (1·060–1·296) 0·0019
Ward†
Medical ward 0·398 (0·279–0·567) <0·0001
Surgical ward 1·237 (0·916–1·669) 0·17
Cardiology ward 1·279 (0·955–1·714) 0·10
Period‡
Period 1 1·354 (0·978–1·876) 0·0679
Period 2 1·193 (0·860–1·657) 0·29
Period 3 0·679 (0·465–0·99) 0·0444
Period 1 medical ward§ 1·713 (1·084–2·708) 0·0212
Period 1 surgical ward§ 0·492 (0·328–0·738) 0·0006
Period 1 cardiology ward§ 0·474 (0·318–0·706) 0·0002
Period 2 medical ward§ 1·249 (0·733–2·129) 0·41
Period 2 surgical ward§ 0·724 (0·480–1·093) 0·12
Period 2 cardiology ward§ 0·74 (0·493–1·11) 0·15
Period 3 medical ward§ 2·126 (1·258–3·591) 0·0048
Period 3 surgical ward§ 1·747 (1·113–2·741) 0·0153
Period 3 cardiology ward§ 1·104 (0·705–1·728) 0·67
*Male was used as reference. †Renal ward was used as reference. ‡Period 4 was 
used as reference. §Interaction exists between any two of these variables.
Table 5: Factors associated with medication error rates during the study 
period
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which could be an important area for future work and 
the customisation of electronic prescribing systems, as 
targeting one type of error for prevention might have 
the added benefit of reducing other error types. More 
advanced and patient-specific clinical decision support, 
which integrates information from the patient’s medical 
record, could possibly inform clinicians if they were to 
prescribe an inappropriate dose and associated frequency. 
Medicine-reconciliation errors also occurred alongside 
dose errors, highlighting the admission stage as a time 
of potential risk. Hellström and colleagues found that 
313 (47%) of 670 patients had a medication-history error 
on admis sion, one of the most common error types being 
wrong dose error.20 Although advanced clinical decision 
support could potentially help reduce the rate of such 
errors, increased involvement of pharmacy services at the 
point of admission21 and improved access to medication 
infor mation collected in primary care are also crucial.22
Our study had a few limitations. First, different clinical 
pharmacists collected data for three of the study wards 
over the study periods and, although regular meetings 
were held between the study team and senior clinical 
pharmacists, it is still possible that there might have been 
subtle differences between how these pharmacists clas-
sified errors. We, therefore, acknowledge that the lack 
of inter-rater reliability data is a limitation of our work. 
Second, it is also possible that pharmacists’ discussion of 
errors with physicians resulted in a learning effect, which 
contributed to the reduced number of certain types of 
error over time. Third, since this study began, a new 
standardised medication error classification system has 
been developed, which includes a tool specifically 
designed to classify medicine-reconciliation errors.23,24 
Fourth, data were collected from four wards at one UK 
hospital trust, which might limit the generalisability of 
our findings. Fifth, we acknowledge that interrogating 
the system with a retract and reorder tool might have 
yielded additional information about potential errors, 
although this investigation was beyond the scope of our 
study.25 Future studies should consider the use of such 
tools. Finally, although the pharmacists recorded whether 
the electronic prescribing system could have contributed 
to the occurrence of a medication error (system-related 
error), we did not investigate the actual cause of these 
errors.
We found that the number of primary medication 
errors per admission did not change significantly over 
the four study periods. However, there was a reduction 
in some types of error and a significant decrease in the 
rates of potential adverse drug event between the first 
three periods and period 4. The identified clustering of 
different types of errors changed across the different 
time periods and this observation could be an area for 
future research, particularly as targeting one type of 
error for prevention might have the added benefit of 
reducing other types of error. Optimisation of electronic 
prescribing systems could contribute to improvements 
in patient safety and help harness the full potential of 
these systems.
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